The Expanding Role of Marine Microbes in Pharmaceutical Development

Overview

Journal Curr Opin Biotechnol

Publisher Elsevier

Specialty Biotechnology

Date 2010 Oct 20

PMID 20956080

Citations 45

Authors

Amanda L Waters

Russell T Hill

Allen R Place

Mark T Hamann

Affiliations

Soon will be listed here.

Abstract

Marine microbes have received growing attention as sources of bioactive metabolites and offer a unique opportunity to both increase the number of marine natural products in clinical trials as well as expedite their development. This review focuses specifically on those molecules currently in the clinical pipeline that are established or highly likely to be produced by bacteria based on expanding circumstantial evidence. We also include an example of how compounds from harmful algal blooms may yield both tools for measuring environmental change as well as leads for pharmaceutical development. An example of the karlotoxin class of compounds isolated from the dinoflagellate Karlodinium veneficum reveals a significant environmental impact in the form of massive fish kills, but also provides opportunities to construct new molecules for the control of cancer and serum cholesterol assisted by tools associated with rational drug design.

Citing Articles

Diversity and Activity of Bacteria Cultured from a Cup-The Sponge .

Itelson L, Merav M, Haymi S, Carmeli S, Ilan M Mar Drugs. 2024; 22(10).

PMID: 39452848 PMC: 11509412. DOI: 10.3390/md22100440.

Marine-Derived Lipases for Enhancing Enrichment of Very-Long-Chain Polyunsaturated Fatty Acids with Reference to Omega-3 Fatty Acids.

Karia M, Kaspal M, Alhattab M, Puri M Mar Drugs. 2024; 22(7).

PMID: 39057410 PMC: 11277628. DOI: 10.3390/md22070301.

Microbial Pathway Thermodynamics: Stoichiometric Models Unveil Anabolic and Catabolic Processes.

Ebenhoh O, Ebeling J, Meyer R, Pohlkotte F, Nies T Life (Basel). 2024; 14(2).

PMID: 38398756 PMC: 10890395. DOI: 10.3390/life14020247.

Isolation and Identification of Culturable Bacteria from South China Seawater and Preliminary Screening of Marine Biocontrol Bacteria.

Guan L, Wang H, Chen J, Yang F, Yang J, Li J Microorganisms. 2023; 11(12).

PMID: 38138077 PMC: 10746102. DOI: 10.3390/microorganisms11122933.

Diverse secondary metabolites are expressed in particle-associated and free-living microorganisms of the permanently anoxic Cariaco Basin.

Geller-McGrath D, Mara P, Taylor G, Suter E, Edgcomb V, Pachiadaki M Nat Commun. 2023; 14(1):656.

PMID: 36746960 PMC: 9902471. DOI: 10.1038/s41467-023-36026-w.

References

Blunt J, Copp B, Hu W, Munro M, Northcote P, Prinsep M . Marine natural products. Nat Prod Rep. 2007; 24(1):31-86. DOI: 10.1039/b603047p. View

Fantini J, Barrantes F . Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009; 1788(11):2345-61. DOI: 10.1016/j.bbamem.2009.08.016. View

Wang D . Neurotoxins from marine dinoflagellates: a brief review. Mar Drugs. 2008; 6(2):349-71. PMC: 2525493. DOI: 10.3390/md20080016. View

Newman D, Cragg G . Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70(3):461-77. DOI: 10.1021/np068054v. View

Luo C, Wang K, Liu D, Li Y, Zhao Q . The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell Mol Immunol. 2008; 5(1):1-7. PMC: 4652918. DOI: 10.1038/cmi.2008.1. View

Davidson S, Allen S, Lim G, Anderson C, Haygood M . Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina. Appl Environ Microbiol. 2001; 67(10):4531-7. PMC: 93199. DOI: 10.1128/AEM.67.10.4531-4537.2001. View

Harvey B, Mironenko T, Sun Y, Hong H, Deng Z, Leadlay P . Insights into polyether biosynthesis from analysis of the nigericin biosynthetic gene cluster in Streptomyces sp. DSM4137. Chem Biol. 2007; 14(6):703-14. DOI: 10.1016/j.chembiol.2007.05.011. View

Gulder T, Moore B . Chasing the treasures of the sea - bacterial marine natural products. Curr Opin Microbiol. 2009; 12(3):252-60. PMC: 2695832. DOI: 10.1016/j.mib.2009.05.002. View

Beer L, Moore B . Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropica. Org Lett. 2007; 9(5):845-8. DOI: 10.1021/ol063102o. View

10.

Li Y, Park M, Ye S, Kim C, Kim Y . Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006; 168(4):1107-18. PMC: 1606567. DOI: 10.2353/ajpath.2006.050959. View

11.

Mikami Y, Takahashi K, Yazawa K, Arai T, Namikoshi M, Iwasaki S . Biosynthetic studies on saframycin A, a quinone antitumor antibiotic produced by Streptomyces lavendulae. J Biol Chem. 1985; 260(1):344-8. View

12.

Hoshi M, Endo T . Microbial and chemical conversion of antibiotic K41. II. Preparation of K41-DA1, -DA2 and -DA3 deamicetosyl derivatives of antibiotic K41. J Antibiot (Tokyo). 2001; 53(10):1154-7. DOI: 10.7164/antibiotics.53.1154. View

13.

Sheng J, Malkiel E, Katz J, Adolf J, Place A . A dinoflagellate exploits toxins to immobilize prey prior to ingestion. Proc Natl Acad Sci U S A. 2010; 107(5):2082-7. PMC: 2836682. DOI: 10.1073/pnas.0912254107. View

14.

Ocio E, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L . Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood. 2008; 113(16):3781-91. DOI: 10.1182/blood-2008-09-177774. View

15.

Peng J, Place A, Yoshida W, Anklin C, Hamann M . Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum. J Am Chem Soc. 2010; 132(10):3277-9. PMC: 2836391. DOI: 10.1021/ja9091853. View

16.

Harrigan G, Yoshida W, Moore R, Nagle D, Park P, Biggs J . Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod. 1998; 61(10):1221-5. DOI: 10.1021/np9801211. View

17.

Newman S . Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs. 2007; 8(12):1057-66. View

18.

Pettit G, Kamano Y, Fujii Y, Herald C, Inoue M, Brown P . Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod. 1981; 44(4):482-5. DOI: 10.1021/np50016a016. View

19.

Mayer A, Glaser K, Cuevas C, Jacobs R, Kem W, Little R . The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci. 2010; 31(6):255-65. DOI: 10.1016/j.tips.2010.02.005. View

20.

Yamazaki Y, Sumikura M, Hidaka K, Yasui H, Kiso Y, Yakushiji F . Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin. Bioorg Med Chem. 2010; 18(9):3169-74. DOI: 10.1016/j.bmc.2010.03.037. View